WuXi STA is opening a new large-scale oligonucleotide and peptide manufacturing facility.
WuXi STA, a subsidiary of WuXi AppTec, is opening a new large-scale continuous manufacturing plant at its Changzhou campus. The facility will focus on increasing capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide.
The new oligonucleotide plant will be 30,570 sq. ft. and will include four large-scale oligonucleotide production lines and more than 20 small-to-mid-scale production lines that increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.
The peptide plant will be 22,260 sq. ft. and feature three new production lines with reactors that can accommodate up to 1000 L, increasing WuXi STA’s overall Solid Phase Peptide Synthesis (SPPS) total reactor volume to 6490 L.
“We are pleased to support our global partners in their efforts to develop new modality therapies for patients in need,” said Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, in a press release. “WuXi STA is committed to enabling partners by enhancing our new modality CRDMO platform’s capacity and capability to expedite the development and commercialization of more innovative therapies to benefit patients worldwide.”
Source: WuXi AppTec
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.